Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.52

+0.4%

12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (4898)	11/7/2001 4:21:01 PM
From: Icebrg	Read Replies (2) of 52153

Re.: Psoriasis market. Adams, Harkness & Hill put out a 40+ page psoriasis report in August. For those finding their way around their site the report can be picked up under the "search name" Abgenix. Most probably under other names too as long as AHH are covering the companies in question. Anyhow, these are AHHs estimate of the market for psoriasis drugs year 2006. They have calculated with a yearly drug cost of USD 7.500, which however they admit might be too low for some of the companies. Turnover is in mUSD. Drug...........US...........Europe.......Total Xanelim........675..........325.........1.000 Amevive........270..........122...........392 Remicade.......145...........35...........180 Enbrel.........655............-...........655 (ps. arthritis) Zenepax........207...........38...........245 ABX-IL8.........63...........12............75 IDEC-114.........-............-.............- MEDI-507.......275............-...........275 They seem to believe that Amevive will start losing sales to the relative newcomers like Zenepax and MEDI-507 in 2006 compared to 2005, while for example sales of Xanelim continues to increase. Ice

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next